BNP Paribas Arbitrage SA boosted its position in shares of Agilent Technologies Inc (NYSE:A) by 38.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 667,402 shares of the medical research company’s stock after buying an additional 186,812 shares during the period. BNP Paribas Arbitrage SA owned approximately 0.21% of Agilent Technologies worth $35,286,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its position in shares of Agilent Technologies by 11.8% in the fourth quarter. FMR LLC now owns 20,784,414 shares of the medical research company’s stock valued at $946,938,000 after buying an additional 2,200,865 shares during the last quarter. State Street Corp boosted its position in shares of Agilent Technologies by 4.7% in the fourth quarter. State Street Corp now owns 14,309,907 shares of the medical research company’s stock valued at $651,951,000 after buying an additional 648,254 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Agilent Technologies by 19.7% in the third quarter. Victory Capital Management Inc. now owns 4,794,946 shares of the medical research company’s stock valued at $225,794,000 after buying an additional 790,219 shares during the last quarter. Norges Bank bought a new position in shares of Agilent Technologies during the fourth quarter valued at approximately $118,636,000. Finally, Janus Capital Management LLC boosted its position in shares of Agilent Technologies by 26.3% in the fourth quarter. Janus Capital Management LLC now owns 2,361,339 shares of the medical research company’s stock valued at $107,583,000 after buying an additional 491,803 shares during the last quarter.
Shares of Agilent Technologies Inc (NYSE:A) traded up 0.50% during mid-day trading on Friday, reaching $56.13. 1,653,441 shares of the company were exchanged. The firm has a 50-day moving average price of $54.57 and a 200 day moving average price of $49.85. The stock has a market capitalization of $18.09 billion, a P/E ratio of 36.00 and a beta of 1.19. Agilent Technologies Inc has a 12 month low of $41.98 and a 12 month high of $58.38.
Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, February 14th. The medical research company reported $0.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.04. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.05 billion. Agilent Technologies had a net margin of 10.99% and a return on equity of 15.49%. The company’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.46 earnings per share. Equities research analysts anticipate that Agilent Technologies Inc will post $2.16 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 26th. Investors of record on Monday, July 3rd will be paid a dividend of $0.132 per share. This represents a $0.53 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date is Thursday, June 29th. Agilent Technologies’s dividend payout ratio (DPR) is 37.59%.
WARNING: “Agilent Technologies Inc (A) Shares Bought by BNP Paribas Arbitrage SA” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2017/05/19/bnp-paribas-arbitrage-sa-increases-stake-in-agilent-technologies-inc-a-updated.html.
A has been the topic of several research analyst reports. Morgan Stanley raised shares of Agilent Technologies from an “equal weight” rating to an “overweight” rating and set a $62.00 price target on the stock in a research report on Wednesday, March 15th. Jefferies Group LLC reiterated a “buy” rating and set a $59.00 price objective on shares of Agilent Technologies in a research note on Friday, March 17th. Zacks Investment Research upgraded shares of Agilent Technologies from a “sell” rating to a “hold” rating in a research note on Friday, February 17th. Janney Montgomery Scott increased their price objective on shares of Agilent Technologies from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 13th. Finally, Deutsche Bank AG restated a “buy” rating and issued a $58.00 price target (up previously from $56.00) on shares of Agilent Technologies in a research note on Sunday, April 2nd. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Agilent Technologies presently has an average rating of “Buy” and an average target price of $55.46.
In other Agilent Technologies news, VP Rodney Gonsalves sold 8,496 shares of the company’s stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $52.05, for a total value of $442,216.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael R. Mcmullen sold 32,511 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $55.48, for a total transaction of $1,803,710.28. Following the completion of the sale, the chief executive officer now directly owns 260,346 shares of the company’s stock, valued at approximately $14,443,996.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,614 shares of company stock valued at $2,934,903.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.